Researchers from UCSF played major roles in five significant multicenter studies of lung disease published in The New England Journal of Medicine.
May 13, 2014
UCSF scientists have found that industry claims about e-cigarettes are unsupported by the evidence to date, including claims that they help smokers quit.
May 08, 2014
UCSF Medical Center has the highest one-year survival rate in the nation, among institutions performing more than 20 adult lung transplants each year, according to data from the Scientific Registry of Transplant Recipients.
December 02, 2013
World-renowned scientists and public health experts will present the latest science and treatment strategies for tuberculosis at “The Century Ahead: Tuberculosis Science, Public Health and Policy,” a symposium marking the 100th anniversary of the founding of California’s TB control program.
November 11, 2013
UCSF scientists were able to arrest, and even reverse, tissue scarring of the liver, kidneys and lungs in mice. The scarring, also known as fibrosis, is a major factor in nearly half of all deaths in developed countries.
October 14, 2013
A team of UCSF researchers developing cell-based therapies for acute respiratory distress syndrome benefited from advisors who helped identify gaps in their development plan.
November 02, 2012
The 10,911-foot view from the top of Cathedral Peak in Yosemite National Park is a familiar sight for Rowan Jimenez. It marked a triumphant return from his double lung transplant surgery.
November 01, 2012
A new molecular test developed by doctors at UCSF may give doctors the ability to better predict post-operative early-stage lung cancer mortality.
September 11, 2012
For two decades, asthma treatment for millions of people with a milder form of the disease has consisted of daily inhaled steroid medicine to reduce inflammation. Now, a new study has found that asthmatics who take the low-dose medication as a daily routine do no better than those who turn to their inhalers only when they have symptoms.
July 01, 2012
People with lung cancer who are treated with the drug Tarceva face a daunting uncertainty: although their tumors may initially shrink, it's not a question of whether their cancer will return—it's a question of when. And for far too many, it happens far too soon.